Vasodilator effects of cromakalim and HA 1077 in diabetic rat aorta

Simple item page
dc.contributor.authorGurpinar T.
dc.contributor.authorGok S.
dc.date.accessioned2024-07-22T08:19:46Z
dc.date.available2024-07-22T08:19:46Z
dc.date.issued2012
dc.description.abstractBACKGROUND: Impairment of the vasorelaxant responses have been reported in diabetes mellitus. In this study, the roles of the KATP channel and rho kinase pathway were evaluated by using the KATP channel opener cromakalim and Rho-kinase inhibitor HA 1077 in diabetic rat aorta. METHODS: Adult male Wistar rats weighing (250-300 g) were divided into diabetic and control groups. Diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 55 mg/kg/i.p). RESULTS: Vasodilator responses induced by cromakalim (10-7 to 10-3M) and HA 1077 (10-6 to 10-4M) were significantly less in diabetic rings compared with control rings (p <0.01). The decrease in the relaxant effect of cromakalim was more in endothelium-denuded rings compared to the endothelium-intact rings (p <0.05). There were no significant differences between endothelium intact and nonintact rings in the presence of HA 1077. When two drugs were administered together, relaxation was significantly less than with seperate administration of each drug in the diabetic group (p <0.01). Pre-treatment with N omeganitro- L-arginine methylester (L-NAME) (10-6 to 10-4 M), an NO synthase inhibitor, significantly decreased the relaxant response to cromakalime and HA 1077 in both the control and diabetic groups (p <0.05). CONCLUSIONS: These results suggest that the impaired relaxant effects were further decreased depending on KATPchannel activity but the effects of Rho-kinase enzyme inhibitors on relaxation responses were not significantly changed in diabetes mellitus.
dc.identifier.DOI-ID10.4414/smw.2012.13558
dc.identifier.issn14247860
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17838
dc.language.isoEnglish
dc.publisherSMW supporting association
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subject1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
dc.subjectAnimals
dc.subjectAorta
dc.subjectCromakalim
dc.subjectDiabetes Mellitus
dc.subjectKATP Channels
dc.subjectMale
dc.subjectMuscle, Smooth, Vascular
dc.subjectRats
dc.subjectRats, Wistar
dc.subjectrho-Associated Kinases
dc.subjectSignal Transduction
dc.subjectStreptozocin
dc.subjectVasodilation
dc.subjectVasodilator Agents
dc.subjectadenosine triphosphate sensitive potassium channel
dc.subjectcromakalim
dc.subjectfasudil
dc.subjectn(g) nitroarginine methyl ester
dc.subjectRho kinase
dc.subjectstreptozocin
dc.subject1 (5 isoquinolinesulfonyl) 2 methylpiperazine
dc.subjectadenosine triphosphate sensitive potassium channel
dc.subjectcromakalim
dc.subjectdrug derivative
dc.subjectfasudil
dc.subjectRho kinase
dc.subjectvasodilator agent
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectaorta
dc.subjectartery endothelium
dc.subjectarticle
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectmale
dc.subjectnonhuman
dc.subjectrat
dc.subjectstreptozocin diabetes
dc.subjectvasodilatation
dc.subjectWistar rat
dc.subjectanimal
dc.subjectchemically induced disorder
dc.subjectdiabetes mellitus
dc.subjectenzymology
dc.subjectin vitro study
dc.subjectmetabolism
dc.subjectpathophysiology
dc.subjectsignal transduction
dc.subjectvascular smooth muscle
dc.subjectvasodilatation
dc.titleVasodilator effects of cromakalim and HA 1077 in diabetic rat aorta
dc.typeArticle

Files

Collections

Scopus Koleksiyonu